These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 11232358

  • 1. Nontransplant treatment of tyrosinemia.
    Holme E, Lindstedt S.
    Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
    [Abstract] [Full Text] [Related]

  • 2. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E, Cornejo V, Arias C, Cabello JF, Castro G, Fernández E, de la Parra A.
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J, Vilaseca Buscà MA, Lambruschini Ferri N, Mas Comas A, González Pascual E, Holme E.
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [Abstract] [Full Text] [Related]

  • 9. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):e132. PubMed ID: 27701365
    [No Abstract] [Full Text] [Related]

  • 10. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ, van Hasselt P, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, Bijleveld CM, van Spronsen FJ.
    Mol Genet Metab; 2006 Dec 10; 89(4):310-5. PubMed ID: 17008115
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
    Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touati G.
    J Inherit Metab Dis; 2008 Feb 10; 31(1):81-7. PubMed ID: 18214711
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN, Venugopalan P.
    Ann Trop Paediatr; 2004 Sep 10; 24(3):259-65. PubMed ID: 15479577
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.